Evaluation of Drug and Vaccine Candidates in the Human Malaria/Aotus Monkey Model
Final rept. 1 May 1996-28 Feb 2001
PROMED TRADING S A MIAMI FL
Pagination or Media Count:
This report presents data 1 On the evaluation of antimalarial drugs, and 2 plasmid DNA and recombinant protein malaria vaccines in the AotusPlasmodium falciparum and vivax model. During the course of these experiments neither Aotus immunized ID with AMA-1, EBA-1 75 and MSP-1 plasmids alone or in combination with or without aGMCSF were protected against a P. falciparum FVO challenge A C2A clone P. falciparum was adapted to intact and splenectomized Aotus. Chloroquine resistance reversal was achieved in Aotus infected with the AMRU-1 strain of P. vivax by using chloroquine and prochiorperazine in combination. Oligodeoxynucleotides when given intramuscularly to Aotus improved immunogenicity of a P. falciparum PADRE 45 peptide immunogen. A significant degree cross-protector was developed in FVO immune Aotus that were challenged with an heterologous CAMP strain of P. falciparum. Immunization with a plasmid encoding region II of EBA-1 75 followed with a recombinant protein boost, partially protected Aotus monkeys against P. falciparum challenge. Both Artelinic Acid and Artesunic Acid at 8-32 mgkg orally for five days were effective at clearing parasitemia in P. falciparum FVO inoculated Aotus. Aotus immunized with plasmids andor recombinant MSP142 were partially protected against a P. falciparum FVO challenge.
- Medicine and Medical Research